🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

23 results for “Third” Clear

  1. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  2. Triptolide Wilfordii

    Peking University Third Hospital

    HIV-infection/AIDS

    phase 3 small molecule completed

    1 trial

  3. 68Ga-NY104 PET/CT

    Peking University Third Hospital

    Clear Cell Renal Cell Carcinoma

    phase 2 other active

    1 trial

  4. 68Ga-Pentixafor

    Peking University Third Hospital

    Cushing s Syndrome

    phase 2 small molecule active

    1 trial

  5. Glofitamab

    Peking University Third Hospital

    MCL

    phase 2 small molecule active

    1 trial

  6. JNJ-73841937, JNJ-61186372, Zirabev 25 mg/ml concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.

    phase 2 small molecule active

    1 trial

  7. Luveris

    Peking University Third Hospital

    Infertility

    phase 2 small molecule active

    1 trial

  8. Roxadustat

    Peking University Third Hospital

    Coronary Artery Bypass

    phase 2 small molecule terminated

    1 trial

  9. recombinant human endostatin

    Peking University Third Hospital

    Melanoma

    phase 2 small molecule active

    1 trial

  10. A Clinical Study to Evaluate the Safety and Pharmacokinetics of JNJ- 73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

    Janssen-Cilag International N.V.

    Advanced Non-Small Cell Lung Cancer

    phase 1 other active

    1 trial

  11. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  12. CAR-T

    The Third Affiliated Hospital of Southern Medical University

    Multiple Myeloma

    phase 1 mab active

    1 trial

  13. Dexmedetomidine

    Peking University Third Hospital

    Breast Cancer

    approved small molecule completed

    1 trial

  14. Dexmedetomidine

    Peking University Third Hospital

    Aged

    approved small molecule completed

    1 trial

  15. Peginterferon alfa

    Third Affiliated Hospital, Sun Yat-Sen University

    Chronic Hepatitis B

    approved small molecule active

    1 trial

  16. ticagrelor + ASA

    Peking University Third Hospital

    Cerebrovascular Accident

    approved small molecule completed

    1 trial

  17. Combination Product: Conventional third-line therapy

    The First People's Hospital of Lianyungang

    Colorectal Cancer (CRC)

    other active

    1 trial

  18. Combination of targeted biopsy and systematic biopsy

    Peking University Third Hospital

    Prostate Cancer

    other completed

    1 trial

  19. Conventional third-line therapy

    The First People's Hospital of Lianyungang

    Colorectal Cancer (CRC)

    other active

    1 trial

  20. ERA

    Peking University Third Hospital

    Infertility, Female

    other active

    1 trial

  21. Protocol-based management of perioperative antithrombotic therapy

    Peking University Third Hospital

    Antithrombotic Therapy

    small molecule active

    1 trial

  22. chlorhexidine acetate gargle

    Peking University Third Hospital

    Esophageal Cancer

    small molecule active

    1 trial

  23. glucocorticoid plus iguratimod

    Peking University Third Hospital

    Autoimmune Diseases

    small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources